X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Regeneron and Sonoma will research and develop Treg-based Cell Therapies for ulcerative colitis, Crohn’s disease and two other undisclosed indications, through VelociSuite® technologies for the discovery and characterization of fully human antibodies and T cell receptors.
Lead Product(s): Treg-based Cell Therapy
Therapeutic Area: Gastroenterology Product Name: Undislcosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: $120.0 million Upfront Cash: $75.0 million
Deal Type: Collaboration March 28, 2023
Details:
SBT115301, is a biologic designed to eliminate highly activated effector T cells that are dominant in autoimmune and inflammatory disease, is CD2-binding fusion protein that resets microenvironment by selectively depleting and inactivating these Teff cells at site of disease.
Lead Product(s): SBT115301
Therapeutic Area: Immunology Product Name: SBT115301
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
SBT-77-7101, a novel CAR-based Treg cell therapy for patients with refractory rheumatoid arthritis. Sonoma Biotherapeutics’ platform and product candidates aim to restore immune system balance through complementary Treg therapy and effector T cell conditioning.
Lead Product(s): SBT-77-7101
Therapeutic Area: Immunology Product Name: SBT-77-7101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $265.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 04, 2021
Details:
The series A funding is to advance regulatory T cell therapy in autoimmune and degenerative diseases.
Lead Product(s): Treg therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lyell Immunopharma
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
